The Zhitong Finance App learned that the latest data from the Hong Kong Stock Exchange shows that on July 30, Yinnuo Pharmaceutical-B (02591) had a position change, with a total market value of HK$188 million, accounting for 6.03%. The company's shareholders deposited 25.295 million shares in Citibank, increasing their shareholding ratio by 6.02%.

According to Yinnuo Pharmaceutical's annual results for the year ended December 31, 2025, the Group generated revenue of approximately 131.5 billion yuan (RMB, same below), mainly from sales of espallotide α in China. Net loss of 341 million yuan, up 95.4% year on year; basic loss per share was 0.79 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.